USPTO serial 99007063
OUTPACE
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- THINGVOLD, CALDER J
- Law office
- TMO LAW OFFICE 135
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with OUTPACE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Seattle, WA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sydney R. Jensen
411 Borel Avenue, Suite 603San Mateo, CA 94402United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Drug discovery services; pharmaceutical drug development services; product research and development; scientific research and development services; pharmaceutical research and development; development of pharmaceutical preparations and drugs; medical and scientific research and development services, namely, identification, production and development of therapeutics, cell therapies, bioengineered cells and proteins for the treatment and prevention of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; medical and scientific research and development services, namely, identification, production and development of cell therapy solutions, namely protein design and custom cell programming; scientific, medical, biotechnology, biomedical, and pharmaceutical research, development, testing and analysis services; medical and scientific research and development services, namely, protein engineering and design services; scientific and medical services, namely, human cell programming services; scientific research, development, discovery and consulting services in the fields of cell therapy and immuno-oncology; scientific research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical research; clinical research in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; scientific research and development, scientific laboratory services, medical and scientific research, biotechnology research and synthetic biology research, all of the foregoing relating to human beings; development of pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; development of pharmaceutical preparations and drugs in the field of immunotherapy; development of pharmaceutical preparations and drugs in the field of cell therapy; development of pharmaceutical preparations and drugs in the field of gene therapy; medical research laboratory services, namely, biological tissue material processing and analysis in the field of cell therapy and immuno-oncology; biotechnology scientific laboratory services; scientific and medical research laboratory services; genetic engineering services, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; genetic engineering of biological cells, cellular targets, proteins, and antibodies for others; providing a website featuring information in the scientific, medical, biotechnology, biomedical, and pharmaceutical fields for the prevention and treatment of human diseases, disorders and conditions; provision of information about scientific and medical research in the field of drug discovery, development and testing; providing a website featuring information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of drug discovery, development and testing; provision of information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; providing a website featuring information about prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of the prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; provision of information about prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of cell therapy and immuno-oncology; providing a website featuring information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of cell therapy and immuno-oncology; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing a website featuring information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of pharmaceuticals and clinical trials; provision of scientific and medical research information in the fields of biotechnology, biomedical, and pharmaceuticals; providing information about medical research relating to the diagnostic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of human diseases, disorders and conditions; | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 22, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Nov 21, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 21, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 21, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 1, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 1, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 1, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 3, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 3, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 3, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 27, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 17, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 17, 2025 | NWAP | NEW APPLICATION ENTERED | — |